Evidence-based guidelines for cardiovascular disease prevention in women

Journal of the American College of Cardiology

Volumn 43, Issue 5, 2004, Pages 900-921

  Mosca, Lori ^a   Appel, Lawrence J ^a   Benjamin, Emelia J ^a   Berra, Kathy ^a,c   Chandra Strobos, Nisha ^a   Fabunmi, Rosalind P ^a   Grady, Deborah ^e   Haan, Constance K ^k   Hayes, Sharonne N ^b   Judelson, Debra R ^f   Keenan, Nora L ^h   McBride, Patrick ^a   Oparil, Suzanne ^a   Ouyang, Pamela ^a   Oz, Mehmet C ^a   Mendelsohn, Michael E ^a   Pasternak, Richard C ^a   Pinn, Vivian W ^j   Robertson, Rose Marie ^a   Schenck Gustafsson, Karin ^a   Sila, Cathy A ^a   Smith Jr , Sidney C ^l   Sopko, George ⁱ   Taylor, Anne L ^g   Walsh, Brian W ^d   Wenger, Nanette K ^a   Williams, Christine L ^a   more..

^a AMERICAN HEART ASSOCIATION   (United States)

^b AMERICAN COLLEGE OF CARDIOLOGY   (United States)

^c Amer College of Nurse Practitioners   (United States)

^d Amer Coll Obstetricians G   (United States)

^e AMERICAN COLLEGE OF PHYSICIANS   (United States)

^f American Medical Women's Association   (United States)

^g Association of Black Cardiologists

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁱ NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^j Office of Research on Women's Health   (United States)

^k The Society of Thoracic Surgeons   (United States)

^l WORLD HEART FEDERATION   (Switzerland)

more..

Author keywords

AHA Scientific Statements; Cardiovascular diseases; Prevention; Risk factors; Women

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FOLIC ACID; LIPID; NICOTINIC ACID; OMEGA 3 FATTY ACID; RECOMBINANT HORMONE; WARFARIN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEPRESSION; DIET SUPPLEMENTATION; DIET THERAPY; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE ORGANIZATION; HEART ATRIUM FIBRILLATION; HEART REHABILITATION; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; LIFESTYLE; META ANALYSIS; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SMOKING CESSATION; SOCIAL PSYCHOLOGY; STROKE; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; PRACTICE GUIDELINES; SEX FACTORS; WOMEN'S HEALTH;

EID: 10744222842     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.02.001     Document Type: Review

References (22)

1. Mosca L., Grundy S.M., Judelson D., et al. Guide to preventive cardiology for women. AHA/ACC scientific statement, consensus panel statement. Circulation. 99:1999;2480-2484.
2. American Heart Association. Heart disease and stroke statistics - 2003 update. 2002;American Heart Association, Dallas, TX.
3. Yusuf S., Reddy S., Ounpuu S., et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 104:2001;2746-2753.
4. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Writing group for the Women's Health Initiative investigators. JAMA. 288:2002;321-333. Summary for patients in: CMAJ 2002;167:377-8, and J Fam Pract 2002;51:821.
5. Manson J.E., Hsia J., Johnson K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. Women's Health Initiative investigators. N Engl J Med. 349:2003;523-534.
6. Wassertheil-Smoller S., Hendrix S.L., Limacher M., et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. Women's Health Initiative investigators. JAMA. 289:2003;2673-2684.
7. Heart and Estrogen/Progestin Replacement Study (HERS) research group, Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 280:1998;605-613.
8. Meinert C.L., Gilpin A.K., Unalp A., et al. Gender representation in trials. Control Clin Trials. 21:2000;462-475.
9. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
10. Smith S., Blair S., Bonow R., et al. AHA/ACC scientific statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 104:2001;1577-1579.
11. Pearson T.A., Blair S.N., Daniels S.R., et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 106:2002;388-391.
12. Gibbons R., Smith S., Antman E. American College of Cardiology/American Heart Association Clinical Practice Guidelines: Part I: where do they come from? Circulation. 107:2003;2979-2986.
13. Benjamin E.J., Smith S.C., Cooper R.S., et al. Task Force #1-magnitude of the prevention problem: opportunities and challenges. 33rd Bethesda Conference. J Am Coll Cardiol. 40:2002;588-603.
14. Kris-Etherton P.M., Harris W.S., Appel L.J. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Scientific statement of the American Heart Association Nutrition Committee. Circulation. 106:2002;2747-2757. Erratum in: Circulation 2003;107:512.
15. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure the JNC 7 report. JAMA. 289:2003;2560-2572. Erratum in: JAMA 2003;290:197.
16. American Diabetes Association. Implications of the diabetes control and complications trial. Diabetes Care. 26:(Suppl 1):2003;S25-S27.
17. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type II diabetes with lifestyle intervention or metformin. N Engl J Med. 346:2002;393-403.
18. American College of Obstetricians and Gynecologists. Response to Women's Health Initative Study Results by the American College of Obstetricians and Gynecologists. 2003;. June 3, Available at http://www.acog.com/member_access/ misc/whiResponse.cfm.
19. The North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women September 2003 position statement of The North American Menopause Society. Menopause. 10:2003;497-506.
20. CHD Risk Prediction Group, D'Agostino R.B. Sr, Grundy S., Sullivan L.M., et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 286:2001;180-187.
21. Grundy S.M., D'Agostino R.B. Sr, Mosca L. Cardiovascular risk assessment based on US cohort studies findings from a National Heart, Lung, and Blood institute workshop. Circulation. 104:2001;491-496.
22. Mosca L., Collins P., Herrington D.M., et al. Hormone replacement therapy and cardiovascular disease a statement for healthcare professionals from the American Heart Association. Circulation. 104:2001;499-503.